All In Biotech

Drug Trial Radar · NCT05099822

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-center, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of CC-97489 in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Dec 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

84

Actual

Start

Mar 13, 2020

Primary completion

Jul 11, 2022

Study completion Jul 11, 2022

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Oct 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety, tolerability, of CC-97489

Conditions

  • Healthy Volunteers

Interventions

  • CC-97489Drug

    Specified dose on specified days

  • PlaceboOther

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs)Time frame: 28 days after the last dose
  2. Incidence of Serious Adverse Events (SAEs)Time frame: 28 days after the last dose
  3. Number of participants with clinically significant changes in electrocardiogram parametersTime frame: Day 21
  4. Incidence of clinically significant changes in vital signs: Body temperatureTime frame: Day 21
  5. Incidence of clinically significant changes in vital signs: Respiratory rateTime frame: Day 21
  6. Incidence of clinically significant changes in vital signs: Blood pressureTime frame: Day 21
  7. Incidence of clinically significant changes in vital signs: Heart rateTime frame: Day 21
  8. Incidence of clinically significant changes in clinical laboratory results: Hematology testsTime frame: Day 18
  9. Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry testsTime frame: Day 18
  10. Incidence of clinically significant changes in clinical laboratory results: Urinalysis testsTime frame: Day 18

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 001

    Leuven, Vlaams Brabant, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.